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Abstract
Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1),
has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data
have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent.
Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a
Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D
patients and 1323 controls) using the TaqMan-assay.
Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either
healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean
serum MCP-1 levels are significantly higher in patients with multiple complications (mean=242 ng/ml) compared to
patients without any complications (mean=201 ng/ml) (p=3.5610
26). Furthermore, mean serum MCP-1 is higher in
controls (mean=261 ng/ml) than T1D patients (mean=208 ng/ml) (p,10
223). More importantly, the frequency of subjects
with extremely high levels (.99
th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D
group compared to the control group (odds ratio=0.11, p,10
233).
Conclusion: MCP-1may havea dualrole inT1D and its complications. While very highlevelsofserum MCP-1 may beprotective
against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.
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Introduction
Chemokine (C-C motif) ligand 2 (CCL2) is commonly known as
monocyte chemoattractant protein-1 (MCP-1). It belongs to a
family of secreted proteins involved in immunoregulatory and
inflammatory processes. MCP-1 is structurally related to the CXC
subfamily of cytokines, which are characterized by two cysteines
separated by a single amino acid. This protein displays
chemotactic activity for monocytes and basophils but not for
neutrophils or eosinophils. It binds to chemokine receptors CCR2
and CCR4.
MCP-1 is widely known as a pro-inflammatory cytokine due to
its chemotactic activity. It has been implicated in the pathogenesis
of many diseases characterized by monocytic infiltration, such as
psoriasis, rheumatoid arthritis and atherosclerosis. Elevated MCP-
1 serum levels have been reported in many diseases including
coronary artery disease (CAD), hepatitis, obesity, acute myeloid
leukemia and autoimmune diseases such as rheumatoid arthritis,
chronic autoimmune thyroiditis [1–12].
Although it is less well appreciated, MCP-1 is also known to
have anti-inflammatory properties. MCP-1 can stimulate the
production of IL-4 [13], which is the primary Th-2 cytokine.
Therefore, MCP-1 may play a protective role against some
autoimmune diseases. Consistent with its anti-inflammatory
activity, it was reported that serum MCP-1 levels were decreased
in multiple sclerosis patients compared to healthy controls [14].
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e17822Limited data have been reported on MCP-1 in type 1 diabetes
(T1D) [15–18], an autoimmune disease characterized by lympho-
cyte infiltration into the pancreatic islets and destruction of the
insulin-producing islet b-cells in children and young adults. The
findings range from significantly higher MCP-1 in T1D patients
than controls [17], to no significant difference between T1D and
controls [15], to significantly lower MCP-1 in pre-diabetic
children with islet autoantibodies [18]. Due to the extremely
small sample sizes (15–96 subjects per study group) in these studies,
the results are, at best, inconclusive and inconsistent. Therefore, it
is still unclear what role, if any, MCP-1 may play in the
pathogenesis of T1D and its associated complications.
This study with 2472 T1D patients and 2654 controls was
designed to have sufficient statistical power to answer three main
questions related to the potential role of MCP-1 in T1D and its
complications. 1) Is there a significant difference between T1D
patients and healthy controls in serum MCP-1levels? 2) Do MCP-
1 levels in T1D patients differ according to sex, age, duration of
diabetes, metabolic control as measured by hemoglobin A1c and
the presence of different diabetic complications? 3) Are serum
MCP-1 levels genetically determined by a functional polymor-
phism in the MCP-1 promoter region?
Results
Serum MCP-1 levels in T1D patients and controls
Serum MCP-1 levels were measured using a Luminex assay for
2472 T1D patients and 2654 control subjects. The sex and age
distributions of the samples are presented in Figure 1. Regression
analyses of the controls using MCP-1 as dependent variable and
age as covariate suggested that MCP-1 levels did not differ
according to age or sex of the control subjects (Figure 2a).
Regression of the T1D patients indicated that MCP-1 levels did
not differ according to age (Figure 2b), sex (Figure 2b), the
duration of diabetes (Figure 2d, e and f) or hemoglobin A1c levels
(data not shown).
T1D patients have lower mean MCP-1 than controls
Interestingly, the mean MCP-1 levels were slightly but
significantly lower in the T1D group (mean=208 ng/ml)
compared with the control group (mean=261 ng/ml) (p,10
223,
Figure 3a). The differences between T1D and control subjects are
highly significant in both male (p,10
213) and female groups
(p,10
213) (Figure 3b). Box-plots for the MCP-1 in T1D and
control groups (Figure 3c) also indicated that the 25
th and 75
th
percentiles of MCP-1 levels differ between T1D and control
subjects. Most importantly, a significantly higher percentage of
control subjects (8.9%) had very high MCP-1 levels (defined as
above the 99
th percentile value in patients, 955 ng/ml) compared
to 1% of the T1D subjects (odds ratio=0.11, p,10
233).
Since the control group contains two subsets of subjects, 1190 from
the general population (GP) and 1464 first degree relatives (FDR) of
T1D patients, we further examined whether the serum MCP-1 levels
differ between these two groups. As shown in Figure 3d, the MCP-1
levels are slightly higher in the FDR (mean=282 ng/ml) than GP
controls (mean=236 ng/ml) and both groups are significantly higher
than T1D patients (p,10
220 and 10
29, respectively).
MCP-1 levels are higher in T1D patients with
complications
MCP-1 levels were further examined in T1D patients with
different diabetic complications. With the exception of two
complications (foot ulcer and autonomic neuropathy) that have
smaller numbers of subjects, the mean levels of serum MCP-1are
significantly higherinpatients with a diabeticcomplication including
hypertension, CAD, nephropathy, retinopathy, photocoagulation,
blindness, dyslipidemia, amputation, and peripheral neuropathy
than T1D patients without the respective complication (Table 1).
Furthermore, patients with three or more complications have higher
mean MCP-1 levels than patients with 0–2 complications.
rs1024611 polymorphism and serum MCP-1 levels
A single nucleotide polymorphism (SNP) is located at the 22518
position of the MCP-1 promoter region (rs1024611), which is
genetically associated with several autoimmune diseases [19–21].
The SNP genotypes are also associated with MCP-1 gene
expression in human pancreatic islets [22]. In heterozygous
individuals for the rs1024611 SNP, allele-specific transcription of
MCP-1 has been reported for human peripheral blood mononu-
clear cells treated with the inflammatory cytokine IL-1b [23].
Furthermore, the promoter polymorphism was correlated with
increased serum MCP-1 levels in severe acute pancreatitis [24].
Therefore, the SNP was genotyped for 1764 T1Dpatients and 1323
GP controls to assess a potential genetic association between T1D
and the SNP. The genotypic and allelic frequencies for this SNP are
similar in T1D patients and controls (Table 2), suggesting that the
MCP-1 SNP is not associated with T1D. Furthermore, the potential
association between serum MCP-1 levels and the promoter SNP
genotypes was assessed in the 1384 T1D patients and 702 controls
with both genotype and serum protein data. As shown in Figure 4,
the mean MCP-1 levels do not differ in the three different MCP-1
genotypes in either controls or T1D patients (p.0.1).
Discussion
Serum MCP-1 has been measured in T1D patients with or
without diabetic complications as well as controls in several
previous studies [15–18]. However, all these studies had extremely
small sample sizes ranging from 15 to 96 subjects in each group
and the conclusions from these studies were inconclusive and
inconsistent. In this study, we measured serum MCP-1 in 2472
T1D patients in different age groups and with/without diabetic
complications. The sample size is at least 25 times bigger than the
largest study previously reported on MCP-1. This large dataset
allowed us to examine the various parameters that may influence
serum MCP-1 levels in T1D patients. Our study highlights the
need for large dataset to detect small differences in the means for
subject groups with different health status due to the large
variation in the patient populations. Our results suggested that sex,
age, hemoglobin A1c or duration of diabetes did not have a major
impact on serum MCP-1 in T1D patients. However, we were not
able to examine the relationship between MCP-1 and C-peptide
levels because such data were not available on most subjects.
Interestingly, the mean serum MCP-1 levels are 20–40% higher in
T1D patients with most diabetic complications including hyper-
tension, CAD, nephropathy, retinopathy, photocoagulation,
blindness, dyslipidemia, amputation, and peripheral neuropathy.
These observations are consistent with the general belief that
MCP-1, a potent monocytes attractant, is a proinflammatory
chemokine. Inflammation is a major hallmark of diabetic patients.
Our study suggests that MCP-1 is increased in diabetic patients
with complications, especially those with severe or multiple
complications. It is therefore possible that reducing inflammation
may help improve the health status of diabetic patients. It has
indeed been found that diabetes induces kidney production of
MCP-1 and that MCP-1 may be an important therapeutic target
for diabetic nephropathy [25–28]. MCP-1 levels was also reported
to be elevated in diabetic patients with coronary artery disease
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other complications related to diabetes.
Interestingly, the mean of serum MCP-1 level is slightly but
significantly lower in T1D patients in comparison with healthy
controls.ThesefindingssuggestthatMCP-1mayplaydifferentroles
in the development of T1D versus diabetic complications. Because
MCP-1 is higher in controls than T1D patients, our data may
suggest that MCP-1 may be protective against the development of
T1D. This hypothesis is consistent with a previous study that
reported significantly lower serum MCP-1 levels in prediabetic
children marked by the presence of islet cell autoantibodies [18] . A
protective role of MCP-1 against T1D is plausible based on the
function of the molecule. It has been shown that no inflammatory
infiltrates were detected in transgenic mice with the MCP-1
transgene under the control of the mouse mammary tumor virus
long terminal repeat (MMTV-LTR) despite expression of high
levels of biologically active MCP-1 in several organs and the serum
[31]. One explanation of these findings is that high levels of MCP-1
in the vasculature can desensitize MCP-1 receptors on circulating
monocytes. This hypothesis is consistent with our finding that the
frequency of individuals with very high serum MCP-1 (above the
99
th percentile, Log2=9.9) is significantly higher in controls (8.9%)
than inthe T1Dgroup(1%) (p,10
233).Asecondexplanationofthe
findings is that high serum concentration of MCP-1 may simply
cancel the chemoattractant gradient from the pathological site. A
third explanation is that MCP-1 can stimulate the production of IL-
4, which is the primary Th-2 cytokine, and has anti- inflammatory
property through control of T cell polarization to Th2 responses
[13]. The functional polarization of T cell subsets of lymphocytes
plays a pivotal role in promoting or conferring risk to T1D in both
humans and animal models [32]. An increase in the expression of
Th1 cytokines and a corresponding decline in the production of
Th2 cytokines (IL-4) is correlated with recent-onset T1D [33].
Predominance of high Th1 cytokines is a main factor to cause
destructionof pancreatic b-cells. In contrast,a constitutiverelease of
IL-4 from pancreatic b-cells is able to prevent insulitis development
in NOD-IL-4 transgenic mice [34]. Immune-intervention strategies
have been explored to establish a good environment that is
attributed to a change in the set of autoreactive T cells from their
Th1to the protective Th2 phenotype. MCP-1 may have a dual role
in the pathogenesis of T1D. On one hand, MCP-1’s pro-
inflammatory activity of monocyte chemoattraction may contribute
Figure 1. Summary of demographic information on study subjects.
doi:10.1371/journal.pone.0017822.g001
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hand, very high levels of serum MCP-1 may exert protective effect
against the development of T1D through one or more mechanisms
discussed above.
Finally, the lower MCP-1 observed in T1D patients than controls
may simply reflect the decline of IL-4 during or after T1D
development. IL-4 can regulate and stimulate expression of the
MCP-1 by human endothelial cells [35]. Studies in human and
animal models suggested that IL-4 production by PBMC or T cells
was significantly lower in new-onset T1D patients than the controls
[33]. Therefore, the contribution of MCP-1 to T1D pathogenesis
may depend on its expression levels and the overall immunological
milieu in the at-risk subject. To fully understand its role in T1D
pathogenesis, it must be studied in the context of other immune
molecules including IL-4 and other Th1 and Th2 cytokines and
chemokines. Furthermore, the possible protective role of very high
levels of serum MCP-1 against the development of T1D must be
tested in prediabetic subjects and in a large prospective cohort.
Methods
Ethics statement
This study was approved by the Medical College of Georgia
Institutional review Board. All patients provided written informed
consent for participation in the study and donation of samples.
Patient population
Serum MCP-1 was measured in 2, 472 patients with T1D and
2,654 healthy controls, which consist of 1,464 FDR subjects and
1,190 subjects from the general population (GP). All subjects were
recruited in Georgia, USA, mainly in the Atlanta and Augusta
areas. Autoantibodies were only measured in a subset of patients
andcontrols.C-peptidedatawerenotavailableforthe subjects.The
sex and age distributions for all subjects of and duration of diabetes
for the patients were summarized in Figure 1. A total of 1764 T1D
patients and 1323 GP controls were also genotyped for the SNP
rs1024611 located at nucleotide 22518 of the MCP-1 promoter.
Blood was drawn from all subjects and was allowed to clot at
room temperature for 30 minutes before centrifugation at 3,000 g
at 4uC for 10 minutes. Then bloodsamples forserum were stored in
280 freezers until use. All samples were retrospectively analyzed. In
the experiment, each sample was aliquoted into wells of 96 well v-
bottom plates and each plate contained similar numbers of samples
from T1D patients and controls. From blood collection to the assay,
none of the samples had more than three freeze/thaw cycles and
each sample usually had only one freeze/thaw cycle.
Luminex assay for MCP-1
MCP-1 in serum was measured using a Luminex assay from
RnD Systems (RnD Systems, Minneapolis, MN, USA) according
to manufacturer’s protocol. Briefly, the kit is based on sandwich
Figure 2. Regression graphs of the relationship between serum levels of MCP-1 relative to age of subjects (a, b & c) and duration of
T1D(d,e&f).a)RelativelevelsofMCP-1 asafunctionofAgeinfemales(b=20.005,R=20.06)andmales(b=20.0013,R=20.02)inthecontrolgroup.
b) Relative expression of MCP-1 in serum of T1D females (b=0.005,R=0.11)andmales(b=0.002,R=0.04). c) Meanserum MCP-1 levels (regression lines)
according to age. d) Regression for duration of disease for female patients (b=0.009, R=0.14). e) Regression for duration of disease for male patients
(b=0.005, R=0.08). f) Mean serum MCP-1 levels (regression lines) according to duration of T1D. b: slope of regression, R: correlation coefficient.
doi:10.1371/journal.pone.0017822.g002
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with a specific monoclonal capture antibody. Serum samples were
incubated with the antibody-coupled microspheres after they were
incubated with biotinylated detection antibody before the addition
of streptavidin-phycoerythrin. The captured bead-complexes were
then read by a Bioplex 100 system (Biorad Laboratories, Hercules,
CA, USA) with the following instrument settings: events/bead: 50,
minimum events: 0, Flow rate: 60 ul/min, Sample size: 50 ul,
discriminator gate: 12800. For all the assays median fluorescence
intensity (MFI) were collected.
MCP-1 concentration (pg/ml) for each subject was estimated
using a linear regression fit to the standard curve of recombinant
MCP-1 protein standards included on each plate using a 3-fold
serial dilution series. The log of the observed median fluorescence
intensity (MFI) for the dilution series samples were regressed on the
log of the known concentration for these samples. The concentra-
tionofsubjectsampleswithanMFIthat waseitherabovethelargest
MFI or below the smallest MFI of the known standards were set to
the estimated concentration for the appropriate extreme known
standards. Samples with a CV among microspheres within the well
that was greater than 100 were removed since the MFI for such
wells are unreliable. The estimated MCP-1 concentrations were on
the log scale, and as such, all analyses were conducted using
ln(MCP-1 concentration). Estimation of MCP-1 concentration
using standard curves were conducted using R [36].
Statistical analysis for serum MCP-1 protein
The potential difference between T1D patients, healthy controls
and other subsets of subjects was initially examined using a t-test. The
Figure 3. Serum MCP-1 differences between T1D and control groups. Dash lines mark the 99
th percentile value in controls. Solid lines and
values on the right side represent the mean values of serum MCP-1 in the respective groups. A. Comparison between all T1D and all control subjects.
b. Box plots for T1D and control groups. c. The control group is separated into first degree relatives of T1D (FDR) and general population (GP). d.
Female and male subjects are separately plotted for both T1D and control groups.
doi:10.1371/journal.pone.0017822.g003
Table 1. Serum MCP-1 levels (Log2) in T1D patients with
diabetic complications.
Complications
Subject
(n)
Log 2
Mean Log2 SD Ratio* p-value
No complications 1740 7.65 0.92 – –
Hypertension 326 7.89 0.93 1.18 0.0023
CAD 119 7.96 0.84 1.24 0.0093
Nephropathy 115 7.86 0.83 1.16 0.029
Retinopathy 302 7.90 0.89 1.19 0.00019
Photocoagulation 212 7.92 0.83 1.21 0.00019
Blindness 48 8.07 0.69 1.34 0.00010
Dyslipidemia 419 7.81 1.03 1.12 0.011
Amputation 15 8.09 0.68 1.36 0.050
Foot Ulcer 32 7.76 1.14 1.08 ns
Peripheral Neuropathy 221 7.94 0.80 1.22 3.0E-07
Autonomic Neuropathy 66 7.71 0.75 1.04 ns
Any complications 732 7.80 0.94 1.11 0.00018
Any one complication 273 7.69 0.94 1.03 ns
Any 2 complications 158 7.79 1.04 1.10 0.07
Any 3 or 3+
complications
301 7.92 0.87 1.21 3.5E-06
*Ratio was calculated for each specific category of complication in comparison
to the group without any complication.
doi:10.1371/journal.pone.0017822.t001
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and duration with diabetes was examined using linear regression.
Male and female subjects were analyzed separately and also jointly
analyzed by including sex as a co-variate. For statistical analysis, R was
used for statistical computing and graphics in the present study [36].
SNP genotyping and data analysis
Genotyping of MCP-1 rs1024611 SNP was carried out using
the TaqMan-assay as described previously [37]. The assay was
designed and validated by Applied Biosystems. Amplification
reactions were performed in a 5 ul final volume in optical 384-well
plates. PCR was carried out with 2 min at 50uC, 10 min at 95uC
followed by 40 cycles of 15 s at 95uC and 1 min at 60uC using an
ABI9700 real-time PCR system (Applied Biosystems). The
frequency of alleles and genotypes in the patient subgroups and
normal controls were compared using x
2 test.
Acknowledgments
We thank a number of physicians (Andy Muir, David Brown, N. Spencer
Welch, Paul Davidson, Joseph Johnson, David Robertson, Constance
Baldwin, Melissa Carlucci, Mark Rappaport, Robert Schultz, Vijayasudha
Gunna) and staff members (Kim English, Jessica Leggett, Katherine
Guthrie, Melanie Brown, Deana McFeely, Nellie Jenkins, JoAnn Higdon,
Debbie Ellison, Tami Kinnersley and Ann Simmonds) for their
contribution in sample collection. We are very grateful to all patients
and other volunteers who participated in this study. The authors wish to
thank Dr. Ashok Sharma for his advice on statistical analysis.
Author Contributions
Conceived and designed the experiments: JS SP. Performed the experi-
ments: RG SP HW CX. Analyzed the data: SP JS. Contributed reagents/
materials/analysis tools: BB JR RS SA LS DH. Wrote the paper: RG JS.
References
1. Martinovic I, Abegunewardene N, Seul M, Vosseler M, Horstick G, et al. (2005)
Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for
coronary artery disease. Circ J 69: 1484–1489.
2. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, et al. (2009) CXCL10
and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis
C. Dig Liver Dis 41: 42–48.
3. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, et al. (2009) CXCL10
and CCL2 chemokine serum levels in patients with hepatitis C associated with
autoimmune thyroiditis. J Interferon Cytokine Res 29: 345–351.
4. Antonelli A, Fallahi P, Delle SA, Ferrari SM, Maccheroni M, et al. (2009) High
values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic
arthtritis. Clin Exp Rheumatol 27: 22–27.
5. Antonelli A, Fallahi P, Delle SA, Ferrari SM, Maccheroni M, et al. (2008) High
values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients
with psoriatic arthritis, in presence or absence of autoimmune thyroiditis.
Autoimmunity 41: 537–542.
6. Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, et al. (2008) Th1 and
Th2 chemokine serum levels in systemic sclerosis in the presence or absence of
autoimmune thyroiditis. J Rheumatol 35: 1809–1811.
7. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, et al. (2008) Alpha-
chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with
hepatitis C-associated cryoglobulinemia in the presence or absence of
autoimmune thyroiditis. Metabolism 57: 1270–1277.
8. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, et al. (2008) CXCL10
(alpha) and CCL2 (beta) chemokines in systemic sclerosis–a longitudinal study.
Rheumatology (Oxford) 47: 45–49.
9. Kim CS, Park HS, Kawada T, Kim JH, Lim D, et al. (2006) Circulating levels of
MCP-1 and IL-8 are elevated in human obese subjects and associated with
obesity-related parameters. Int J Obes (Lond) 30: 1347–1355.
10. Kokkotou E, Marafelia P, Mantzos EI, Tritos NA (2002) Serum monocyte
chemoattractant protein-1 is increased in chronic autoimmune thyroiditis.
Metabolism 51: 1489–1493.
Figure 4. Serum MCP-1 values are plotted for each subject based on their 22518A/G SNP genotypes. Means for each group are marked
by the solid lines and the values on the right side.
doi:10.1371/journal.pone.0017822.g004
Table 2. Genotypic and allelic frequencies of MCP-1 SNP.
T1D patients
(n=1764)
AbN controls
(n=1323)
Genotypes
AA 952 (54.0%) 706 (53.4%)
AG 683 (38.7%) 507 (38.3%)
GG 129 (7.3%) 110 (8.3%)
Alleles
A 2587 (73.3%) 1919 (72.5%)
G 941 (26.7%) 727 (27.5%)
doi:10.1371/journal.pone.0017822.t002
CCL2 and Type 1 Diabetes
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e1782211. Mazur G, Wrobel T, Butrym A, Kapelko-Slowik K, Poreba R, et al. (2007)
Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in
acute myeloid leukemia. Neoplasma 54: 285–289.
12. Stankovic A, Slavic V, Stamenkovic B, Kamenov B, Bojanovic M, et al. (2009)
Serum and synovial fluid concentrations of CCL2 (MCP-1) chemokine in
patients suffering rheumatoid arthritis and osteoarthritis reflect disease activity.
Bratisl Lek Listy 110: 641–646.
13. Gu L, Tseng S, Horner RM, Tam C, Loda M, et al. (2000) Control of TH2
polarization by the chemokine monocyte chemoattractant protein-1. Nature
404: 407–411.
14. Scarpini E, Galimberti D, Baron P, Clerici R, Ronzoni M, et al. (2002) IP-10
and MCP-1 levels in CSF and serum from multiple sclerosis patients with
different clinical subtypes of the disease. J Neurol Sci 195: 41–46.
15. Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d’Annunzio G, et al. (2008) Serum
Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly
diagnosed Type 1 diabetes: a longitudinal study. Diabet Med 25: 1349–1353.
16. Kiyici S, Erturk E, Budak F, Ersoy C, Tuncel E, et al. (2006) Serum monocyte
chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic
patients with nephropathy. Arch Med Res 37: 998–1003.
17. Zineh I, Beitelshees AL, Silverstein JH, Haller MJ (2009) Serum monocyte
chemoattractant protein-1 concentrations associate with diabetes status but not
arterial stiffness in children with type 1 diabetes. Diabetes Care 32: 465–467.
18. Hanifi-Moghaddam P, Kappler S, Seissler J, Muller-Scholze S, Martin S, et al.
(2006) Altered chemokine levels in individuals at risk of Type-1 diabetes mellitus.
Diabetic Medicine 23: 156–163.
19. Palmieri O, Latiano A, Salvatori E, Valvano MR, Bossa F, et al. (2010) The
2A2518G Polymorphism of Monocyte Chemoattractant Protein-1 Is Associated
With Crohn’s Disease. Am J Gastroenterol 105: 1586–1594.
20. Radstake TRDJ, Vonk MC, Dekkers M, Schijvenaars MMVA, Treppichio WL,
et al. (2009) The 22518A/G promoter polymorphism in the CCL2 gene is not
associated with systemic sclerosis susceptibility or phenotype: Results from a
multicenter study of European Caucasian patients. Human Immunology 70:
130–133.
21. Park HJ, Yoon SH, Zheng LT, Lee KH, Kim JW, et al. (2007) Association of the
22510A/G chemokine (C-C motif) ligand-2 polymorphism with knee
osteoarthritis in a Korean population. Scand J Rheumatol 36: 299–306.
22. Guerra SD, D’A V, Gualtierotti G, Filipponi F, Boggi U, Simone PD, et al.
(2010) A Common Polymorphism in the Monocyte Chemoattractant Protein-1
(MCP-1) Gene Regulatory Region Influences MCP-1 Expression and Function
of Isolated Human Pancreatic Islets. Transplant Proc 42: 2247–2249.
23. Rovin BH, Lu L, Saxena R (1999) A Novel Polymorphism in the MCP-1 Gene
Regulatory Region That Influences MCP-1 Expression. Biochemical and
Biophysical Research Communications 259: 344–348.
24. Georgios IP, David AS, Haritha A, Janette L, Anna L, et al. (2005) Is the
Monocyte Chemotactic Protein-1 22518 G Allele a Risk Factor for Severe
Acute Pancreatitis? Clin Gastroenterol Hepatol 3: 475–481.
25. Tesch GH (2008) MCP-1/CCL2: a new diagnostic marker and therapeutic
target for progressive renal injury in diabetic nephropathy. American Journal of
Physiology - Renal Physiology 294: F697–F701.
26. Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, et al. (2009) Effect of the
Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on
Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured
Podocytes. Diabetes 58: 2109–2118.
27. Mao Z, Shandong Y, Zhimin Z, Yan C, Xiucai L, et al. (2009) Rosiglitazone
protects diabetic rats against kidney disease through the suppression of renal
moncyte chemoattractant protein-1 expression. J Diabetes Complications 23:
124–129.
28. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, et al. (2007) Inhibition
of MCP-1/CCR2 pathway ameliorates the development of diabetic nephrop-
athy. Biochemical and Biophysical Research Communications 360: 772–777.
29. Harsimran K, Singh AAP, Guruvinder S, Sharda S, Vasudha S (2009) Plasma
monocyte chemoattractant protein-1 as risk marker in type 2 diabetes mellitus
and coronary artery disease in North Indians. Diabetes and Vascular Disease
Research 6: 288–290.
30. Piemonti L, Calori G, Lattuada G, Mercalli A, Ragogna F, et al. (2009)
Association Between Plasma Monocyte Chemoattractant Protein-1 Concentra-
tion and Cardiovascular Disease Mortality in Middle-Aged Diabetic and
Nondiabetic Individuals. Diabetes Care 32: 2105–2110.
31. Gu L, Rutledge B, Fiorillo J, Ernst C, Grewal I, et al. (1997) In vivo properties of
monocyte chemoattractant protein-1. J Leukoc Biol 62: 577–580.
32. Sia C (2005) Imbalance in Th cell polarization and its relevance in type 1
diabetes mellitus. Rev Diabet Stud 2: 182–186.
33. Berman MA, Sandborg CI, Wang Z, Imfeld KL, Zaldivar F, Jr., et al. (1996)
Decreased IL-4 production in new onset type I insulin-dependent diabetes
mellitus. J Immunol 157: 4690–4696.
34. Mueller R, Krahl T, Sarvetnick N (1996) Pancreatic expression of interleukin-4
abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice.
J Exp Med 184: 1093–1099.
35. Rollins BJ, Pober JS (1991) Interleukin-4 induces the synthesis and secretion of
MCP-1/JE by human endothelial cells. Am J Pathol 138: 1315–1319.
36. R Development Core Team (2010) R: A language and environment for
statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
37. Liu S, Wang H, Jin Y, Podolsky R, Reddy MV, et al. (2009) IFIH1
polymorphisms are significantly associated with type 1 diabetes and IFIH1
gene expression in peripheral blood mononuclear cells. Hum Mol Genet 18:
358–365.
CCL2 and Type 1 Diabetes
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e17822